FDA Classifies Post-Birth Chromosome Checker as Safe Class II Device
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting the postnatal chromosomal copy number variation detection system into a special safety category called Class II. This means the device will have clear rules to keep it safe and effective, helping patients get access to new, helpful technology faster. This change affects device makers and aims to cut red tape without compromising safety, with no extra costs announced.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Postnatal CNV Test Reclassified to Class II
The FDA is classifying the postnatal chromosomal copy number variation (CNV) detection system as Class II (special controls). The agency says the special controls will be identified in this order and codified, and that the Class II classification provides a reasonable assurance of safety and effectiveness while reducing regulatory burdens.
Faster Patient Access to CNV Tests
You may get better access to postnatal chromosomal copy number variation detection systems because the FDA says Class II classification will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. The FDA also states the classification provides a reasonable assurance of safety and effectiveness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-16031, Medical Devices; Immunology and Microbiology Devices; Classification of the Anti-Phospholipase A2 Receptor Immunological Test System
The FDA is officially putting the anti-phospholipase A2 receptor test into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get access to this important medical tool faster. Labs and device makers should get ready for these new rules, which aim to make things smoother without extra costs or delays.
Next: 2025-16033, Medical Devices; Radiology Devices; Classification of the Liver Iron Concentration Imaging Companion Diagnostic for Deferasirox
The FDA is officially classifying a special imaging device that helps doctors measure liver iron levels for patients using deferasirox as a Class II device with safety rules. This change means the device will be safer and easier to get, helping patients get better care faster. Medical device makers and patients can expect smoother approvals without extra costs or delays.